Pablo Corral: Why Should Dyslipidemia Be Any Different?
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Liam R. Brunham et al., published in JACC Journals, adding:
“Why should dyslipidemia be any different?
Over the past two decades, medicine has embraced early combination therapy in chronic diseases:
- Hypertension: combination therapy is now recommended for most patients.
- Type 2 diabetes: early combination therapy has become routine to improve glycemic control and cardiovascular outcomes.
Dyslipidemia: why do we still expect statin monotherapy to achieve increasingly ambitious LDL-C goals?
Today’s LDL-C targets are lower than ever. In fact, recent ESC/EAS and ACC/AHA guidelines acknowledge that achieving these goals will frequently require combination lipid-lowering therapy.
Even more importantly, a recent JACC Editorial proposes moving beyond the traditional stepwise intensification toward a ‘distance above target’ strategy: selecting the treatment according to how much additional LDL-C reduction is needed, rather than adding drugs sequentially.
The question is no longer whether combination therapy should be used.
The real question is when.
For many patients at high and very high cardiovascular risk, the answer should be:
From the beginning.
If early combination therapy is the standard for hypertension and diabetes, it should no longer be the exception in dyslipidemia.
Same philosophy. Same goal: reach the target early and reduce cardiovascular risk.”
Title: The Expanding Oral Options for LDL Cholesterol Management: Ain’t No Cholesterol High Enough, Ain’t No Target Low Enough!
Authors: Liam R. Brunham, Michael D. Shapiro, and Vijay Nambi
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI
-
Sep 20, 2026, 09:51Ceasovschih Alexandr: A Closer Look at Lipid Disorders in CKM Syndrome